GlassScriptPhysician profile
Anil S Paramesh
NPI 1255390738
$20,507.91
in general payments reported to CMS, 2019-2025
28 companies · $8,874 in 2025
The $8,874 reported for 2025 was more than what 90% of Transplant Surgery providers received nationally (typical 2025 total: $423).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,303 · 2020: $96.52 · 2021: $426 · 2022: $132 · 2023: $380 · 2024: $9,297 · 2025: $8,874.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $17K · Food and Beverage: $1,650.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $16,900.00 |
| Food and Beverage | $1,650.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Davol INC. | $16,900.00 | 2024-2025 | |
| Intuitive Surgical, INC. | $1,382.89 | 2019-2022 | |
| United Therapeutics Corporation | $388.40 | 2023-2025 | |
| Amgen INC. | $273.63 | 2024-2025 | Krystexxa |
| Gilead Sciences, INC. | $265.28 | 2021-2024 | Epclusa |
| Veloxis Pharmaceuticals, INC. | $239.74 | 2019-2025 | Envarsus |
| Biom'Up France Sas | $147.30 | 2021 | |
| Dilon Technologies, INC. | $137.09 | 2025 | Hemoblast Bellows |
| Sanofi-Aventis U.S. LLC | $117.48 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $107.68 | 2025 | Iqirvo |
| W. L. Gore & Associates, INC. | $89.36 | 2019-2023 | Gore Propaten Vascular Graft |
| Silk Road Medical, INC. | $77.70 | 2021 | |
| Intercept Pharmaceuticals, INC. | $46.17 | 2025 | |
| Medtronic, INC. | $43.13 | 2023-2025 | Ligasure |
| Takeda Pharmaceuticals U.S.A., INC. | $42.25 | 2025 | Livtencity |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $41.64 | 2025 | Rezdiffra |
| Eisai INC. | $37.11 | 2019 | |
| Pfizer INC. | $32.52 | 2020 | |
| Biogen, INC. | $25.30 | 2025 | |
| Ethicon US, LLC | $24.68 | 2019 | |
| Novo Nordisk INC | $16.89 | 2025 | Wegovy |
| Aroa Biosurgery Incorporated | $16.72 | 2022 | |
| Astellas Pharma US INC | $16.42 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $15.08 | 2023 | Jynarque |
| Dova Pharmaceuticals | $11.88 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.57 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anil Paramesh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.